{
  "first_published_at": "2011-01-12", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON105746", 
  "title": "Insulin combined with pioglitazone: risk of cardiac failure", 
  "tags": "{\"parsed_therapeutic\": [\"endocrinology-diabetology-metabolism\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Endocrinology, diabetology and metabolism\"]}", 
  "_document_number": 170, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "endocrinology-diabetology-metabolism"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Insulin combined with pioglitazone: risk of cardiac failure</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: January 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain, and oedema<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Pioglitazone is indicated for the treatment of type 2 diabetes either as monotherapy (brand name Actos&#9660;) or in combination with metformin (brand name Competact&#9660;) and/or a sulphonylurea.</p><p>Pioglitazone is also indicated in combination with insulin for adults with type 2 diabetes with insufficient glycaemic control on insulin for whom metformin is inappropriate because of&nbsp;contraindications or intolerance.</p><p>A European review of the increased incidence of cardiac failure when pioglitazone is used in combination with insulin, especially in patients with predisposing factors, has recommended that the product information for insulin should equally reflect this risk and contain appropriate warnings. The product information for pioglitazone already contains warnings about its use in combination with insulin. Warnings are also being added to the product information for all insulin products.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for health professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure</li>\r\n\t\t\t\t<li>If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain, and oedema</li>\r\n\t\t\t\t<li>Pioglitazone should be discontinued if any deterioration in cardiac status occurs</li>\r\n\t\t\t</ul></div><p><strong>Further information</strong></p><p>BNF section 6.1.1 <a href=\"http://www.medicinescomplete.com/mc/bnf/current/4081.htm\" target=\"_blank\">Insulins</a></p><p>National Prescribing Centre <a href=\"http://www.npci.org.uk/blog/?p=2199\" target=\"_blank\">information on pioglitazone<br></a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Jan 2011, vol 4 issue 6: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Pioglitazone is indicated for the treatment of type 2 diabetes either as monotherapy (brand name Actos&#9660;) or in combination with metformin (brand name Competact&#9660;) and/or a sulphonylurea.</p><p>Pioglitazone is also indicated in combination with insulin for adults with type 2 diabetes with insufficient glycaemic control on insulin for whom metformin is inappropriate because of&#160;contraindications or intolerance.</p><p>A European review of the increased incidence of cardiac failure when pioglitazone is used in combination with insulin, especially in patients with predisposing factors, has recommended that the product information for insulin should equally reflect this risk and contain appropriate warnings. The product information for pioglitazone already contains warnings about its use in combination with insulin. Warnings are also being added to the product information for all insulin products.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for health professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure</li>\r\n\t\t\t\t<li>If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain, and oedema</li>\r\n\t\t\t\t<li>Pioglitazone should be discontinued if any deterioration in cardiac status occurs</li>\r\n\t\t\t</ul></div><p><strong>Further information</strong></p><p>BNF section 6.1.1 <a href=\"http://www.medicinescomplete.com/mc/bnf/current/4081.htm\" target=\"_blank\">Insulins</a></p><p>National Prescribing Centre <a href=\"http://www.npci.org.uk/blog/?p=2199\" target=\"_blank\">information on pioglitazone</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Jan 2011, vol 4 issue 6: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-01-01", 
  "date_last_modified": "2011-01-11", 
  "_assets": [], 
  "_item_id": 170, 
  "summary": "Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain, and oedema", 
  "body": "Article date: January 2011\n\nPioglitazone is indicated for the treatment of type 2 diabetes either as monotherapy (brand name Actos▼) or in combination with metformin (brand name Competact▼) and/or a sulphonylurea.\n\nPioglitazone is also indicated in combination with insulin for adults with type 2 diabetes with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.\n\nA European review of the increased incidence of cardiac failure when pioglitazone is used in combination with insulin, especially in patients with predisposing factors, has recommended that the product information for insulin should equally reflect this risk and contain appropriate warnings. The product information for pioglitazone already contains warnings about its use in combination with insulin. Warnings are also being added to the product information for all insulin products.\n\nAdvice for health professionals:  \n  \n  * Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure  \n  * If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain, and oedema  \n  * Pioglitazone should be discontinued if any deterioration in cardiac status occurs  \n  \nFurther information\n\nBNF section 6.1.1 [Insulins](http://www.medicinescomplete.com/mc/bnf/current/4081.htm)\n\nNational Prescribing Centre [information on pioglitazone](http://www.npci.org.uk/blog/?p=2199)\n\n \n\nArticle citation: Drug Safety Update Jan 2011, vol 4 issue 6: A2.\n"
}